These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 20846522)
61. Biomarkers of Hepatic Dysfunction and Cardiovascular Risk. Lee TB; Kueh MTW; Jain V; Razavi AC; Alebna P; Chew NWS; Mehta A Curr Cardiol Rep; 2023 Dec; 25(12):1783-1795. PubMed ID: 37971635 [TBL] [Abstract][Full Text] [Related]
62. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease. Arriola-Montenegro J; Beas R; Cerna-Viacava R; Chaponan-Lavalle A; Hernandez Randich K; Chambergo-Michilot D; Flores Sanga H; Mutirangura P World J Cardiol; 2023 Jul; 15(7):328-341. PubMed ID: 37576545 [TBL] [Abstract][Full Text] [Related]
63. Association of C-reactive protein with histological, elastographic, and sonographic indices of non-alcoholic fatty liver disease in individuals with severe obesity. Jamialahmadi T; Bo S; Abbasifard M; Sathyapalan T; Jangjoo A; Moallem SA; Almahmeed W; Ashari S; Johnston TP; Sahebkar A J Health Popul Nutr; 2023 Apr; 42(1):30. PubMed ID: 37029427 [TBL] [Abstract][Full Text] [Related]
64. Effect of Dietary Intervention, with or without Cointerventions, on Inflammatory Markers in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Hall RL; George ES; Tierney AC; Reddy AJ Adv Nutr; 2023 May; 14(3):475-499. PubMed ID: 36796436 [TBL] [Abstract][Full Text] [Related]
65. Association between high-sensitivity-CRP and liver elastography and cardiac ischemic diseases in patients with fatty liver. Nayebi M; Seyedian SS; Hashemi SJ; Parsi A; Hajiani E J Family Med Prim Care; 2022 Sep; 11(9):5495-5499. PubMed ID: 36505545 [TBL] [Abstract][Full Text] [Related]
66. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Portincasa P; Bonfrate L; Khalil M; Angelis M; Calabrese FM; D'Amato M; Wang DQ; Di Ciaula A Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052763 [TBL] [Abstract][Full Text] [Related]
67. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Lambrecht J; Tacke F Front Immunol; 2020; 11():634409. PubMed ID: 33633748 [TBL] [Abstract][Full Text] [Related]
68. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Chiriac S; Stanciu C; Girleanu I; Cojocariu C; Sfarti C; Singeap AM; Cuciureanu T; Huiban L; Muzica CM; Zenovia S; Nastasa R; Trifan A Can J Gastroenterol Hepatol; 2021; 2021():6696857. PubMed ID: 33505944 [TBL] [Abstract][Full Text] [Related]
69. The Role of Thyroid Hormones and Autoantibodies in Metabolic Dysfunction Associated Fatty Liver Disease: TgAb May Be a Potential Protective Factor. Zhang X; Li R; Chen Y; Dai Y; Chen L; Qin L; Cheng X; Lu Y Front Endocrinol (Lausanne); 2020; 11():598836. PubMed ID: 33363517 [TBL] [Abstract][Full Text] [Related]
70. Factor analysis for the clustering of cardiometabolic risk factors and sedentary behavior, a cross-sectional study. Tsai TY; Hsu PF; Lin CC; Wang YJ; Ding YZ; Liou TL; Wang YW; Huang SS; Chan WL; Lin SJ; Chen JW; Leu HB PLoS One; 2020; 15(11):e0242365. PubMed ID: 33196674 [TBL] [Abstract][Full Text] [Related]
71. Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian Indians: A cross-sectional study. Kumar R; Porwal YC; Dev N; Kumar P; Chakravarthy S; Kumawat A J Family Med Prim Care; 2020 Jan; 9(1):390-394. PubMed ID: 32110624 [TBL] [Abstract][Full Text] [Related]
72. Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Grabherr F; Grander C; Effenberger M; Adolph TE; Tilg H Front Endocrinol (Lausanne); 2019; 10():611. PubMed ID: 31555219 [TBL] [Abstract][Full Text] [Related]
73. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Saltzman ET; Palacios T; Thomsen M; Vitetta L Front Microbiol; 2018; 9():61. PubMed ID: 29441049 [TBL] [Abstract][Full Text] [Related]
74. Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance? Verdelho Machado M GE Port J Gastroenterol; 2017 Jul; 24(4):157-160. PubMed ID: 29255744 [No Abstract] [Full Text] [Related]
75. High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men. Lee J; Yoon K; Ryu S; Chang Y; Kim HR PLoS One; 2017; 12(2):e0172666. PubMed ID: 28234943 [TBL] [Abstract][Full Text] [Related]
76. Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets. Paquissi FC Front Immunol; 2016; 7():490. PubMed ID: 27891128 [TBL] [Abstract][Full Text] [Related]
77. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Wu S; Wu F; Ding Y; Hou J; Bi J; Zhang Z Sci Rep; 2016 Sep; 6():33386. PubMed ID: 27633274 [TBL] [Abstract][Full Text] [Related]
78. Two-hour postload glycemia is associated to an increased risk of NAFLD in healthy subjects with family history of type 2 diabetes: a case control study. Pallotta N; Filardi T; Carnovale A; Nieddu L; Mariani P; Vincoli G; Lenzi A; Morano S Endocrine; 2017 Aug; 57(2):352-355. PubMed ID: 27422790 [No Abstract] [Full Text] [Related]
79. Non-alcoholic fatty liver disease and outcomes in persons with acute coronary syndromes: insights from the GRACE-ALT analysis. Ravichandran L; Goodman SG; Yan AT; Mendelsohn A; Ray JG Heart Asia; 2012; 4(1):137-40. PubMed ID: 27326050 [TBL] [Abstract][Full Text] [Related]
80. Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review. Li XL; Sui JQ; Lu LL; Zhang NN; Xu X; Dong QY; Xin YN; Xuan SY Lipids Health Dis; 2016 Mar; 15():53. PubMed ID: 26965314 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]